Marco Lecis
Research Subjects
Marco Lecis has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Lorenzo Iughetti
Pediatric Unit, Department of Medical and Surgical Sciences of the Mother, Children and Adults, University of Modena and Reggio Emilia, 41125 Modena, Italy
4 shared publications - Ilaria Mariotti
Pediatric Oncology and Hematology Unit, Department of Medical and Surgical Sciences for Mother Children and Adults, University of Modena and Reggio Emilia, 41124 Modena, Italy
2 shared publications A. Luglio
Post Graduate School of Paediatrics, Department of Medical and Surgical Sciences of the Mothers, Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
1 shared publicationAip
1 shared publication- Alberto Berardi
Neonatal Intensive Care Unit, Women’s and Children’s Health Department, University Hospital of Modena, 41124 Modena, Italy
1 shared publication - Alberto Righi
Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, 40316 Bologna, Italy
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (11) , 649
Congenital Spindle-Cell Rhabdomyosarcoma with TEAD1-NCOA2 Fusion: Case Report and Review of the Literature
Background: Spindle-cell and sclerosing rhabdomyosarcomas (ssRMSs) are recently described as a rare variant of rhabdomyosarcoma (RMS), categorized by the World Health Organization classification as a entity distinct from embryonal or alveolar RMSs. Recent studies have shown ssRMSs to be a group of entities with significant morphological overlap but with a great molecular heterogeneity, with some genetic alterations potentially offering a better prognosis. Tumors harboring MYOD1 (p.L122R) mutations usually occur in older children and have a poorer prognosis, while tumors with genetic translocations resulting in fusion genes involving NCOA2 and/or VGLL2 tend to be congenital. Reports in the literature mainly suggest a favorable prognosis for this subset; however, four cases of patients who experienced local progression and distant metastases have recently been described. Outcomes and best treatment options for this subset of patients are therefore not fully established. Methods: We reviewed the current literature about treatment and outcomes of ssRMSs in infants using the PubMed CENTRAL databases, including in our literature search papers published in English in the last ten years. Results: We present a very rare case of a 15-month-old female diagnosed with a spindle-cell rhabdomyosarcoma harboring TEAD1-NCOA2 fusion of the left scapular region. The patient showed no local recurrence at the last follow-up, 4 years after being treated with chemotherapy and surgery. Our literature search identified 1323 records, of which 21 were included in the review. Conclusions: Our case report confirms the few data previously published in the literature, suggesting a good prognosis for this subset of patients. Molecularly defined ssRMSs in infants likely represent a biologically distinct entity which may not require the aggressive multimodal treatment used for other subtypes of rhabdomyosarcoma.
- 27 October 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (11) , 649
Open AccessCongenital Spindle-Cell Rhabdomyosarcoma with TEAD1-NCOA2 Fusion: Case Report and Review of the Literature
Background: Spindle-cell and sclerosing rhabdomyosarcomas (ssRMSs) are recently described as a rare variant of rhabdomyosarcoma (RMS), categorized by the World Health Organization classification as a entity distinct from embryonal or alveolar RMSs. Recent studies have shown ssRMSs to be a group of entities with significant morphological overlap but with a great molecular heterogeneity, with some genetic alterations potentially offering a better prognosis. Tumors harboring MYOD1 (p.L122R) mutations usually occur in older children and have a poorer prognosis, while tumors with genetic translocations resulting in fusion genes involving NCOA2 and/or VGLL2 tend to be congenital. Reports in the literature mainly suggest a favorable prognosis for this subset; however, four cases of patients who experienced local progression and distant metastases have recently been described. Outcomes and best treatment options for this subset of patients are therefore not fully established. Methods: We reviewed the current literature about treatment and outcomes of ssRMSs in infants using the PubMed CENTRAL databases, including in our literature search papers published in English in the last ten years. Results: We present a very rare case of a 15-month-old female diagnosed with a spindle-cell rhabdomyosarcoma harboring TEAD1-NCOA2 fusion of the left scapular region. The patient showed no local recurrence at the last follow-up, 4 years after being treated with chemotherapy and surgery. Our literature search identified 1323 records, of which 21 were included in the review. Conclusions: Our case report confirms the few data previously published in the literature, suggesting a good prognosis for this subset of patients. Molecularly defined ssRMSs in infants likely represent a biologically distinct entity which may not require the aggressive multimodal treatment used for other subtypes of rhabdomyosarcoma.
- Open Access
- 22 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Work participation in inborn errors of immunity: The dual burden on patients and caregivers
Despite improved survival, occupational challenges in with inborn errors of immunity (IEI) patients and their families remain unmeasured. We conducted a nationwide cross-sectional survey promoted by AIP and ImmunITA, including 420 IEI adults and 110 caregivers, integrating occupational data with patient-reported outcome measures. Multivariable models assessed employment and productivity determinants. Overall, 67% of patients were employed, yet half reported reduced capacity, unsafe environments, limited career progression, and stigma. Unemployment was associated with female sex, disability, and lower education. Nondisclosure affected one-fourth of patients and one-fifth of caregivers. Work impairment reached 39%; absenteeism was driven by healthcare demands, while presenteeism was associated with disease burden, psychological distress, and immune dysregulation, but not the Ig administration route. Caregivers showed 34% work impairment, with absenteeism linked to care intensity and presenteeism to psychological distress, patient health, and child caregiving. Child caregivers had greater time demands and more part-time employment. In conclusion, IEI substantially impair work productivity, supporting integration of occupational needs into care to improve social inclusion.
- 22 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Open AccessWork participation in inborn errors of immunity: The dual burden on patients and caregivers
Despite improved survival, occupational challenges in with inborn errors of immunity (IEI) patients and their families remain unmeasured. We conducted a nationwide cross-sectional survey promoted by AIP and ImmunITA, including 420 IEI adults and 110 caregivers, integrating occupational data with patient-reported outcome measures. Multivariable models assessed employment and productivity determinants. Overall, 67% of patients were employed, yet half reported reduced capacity, unsafe environments, limited career progression, and stigma. Unemployment was associated with female sex, disability, and lower education. Nondisclosure affected one-fourth of patients and one-fifth of caregivers. Work impairment reached 39%; absenteeism was driven by healthcare demands, while presenteeism was associated with disease burden, psychological distress, and immune dysregulation, but not the Ig administration route. Caregivers showed 34% work impairment, with absenteeism linked to care intensity and presenteeism to psychological distress, patient health, and child caregiving. Child caregivers had greater time demands and more part-time employment. In conclusion, IEI substantially impair work productivity, supporting integration of occupational needs into care to improve social inclusion.
- Open Access
- 1 January 2023
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2023 (1) , 8470341
Enzyme Replacement Therapy (ERT) on Heart Function Changes the Outcome in Patients with Infantile‐Onset Pompe Disease: A Familial History
Background . Lysosomal acid alpha‐glucosidase (GAA) deficiency, also known as Pompe disease, is an autosomal recessive disorder that leads to the accumulation of glycogen in lysosomes and cytoplasm, resulting in tissue destruction. Infantile‐onset GAA deficiency is characterized by cardiomyopathy and severe generalized hypotonia. Without treatment, most patients die within the first two years of life. The demonstration of reduced GAA activity, followed by sequencing of the GAA gene, confirms the disease. GAA deficiency is currently treated with enzyme replacement therapy (ERT) with improved clinical outcomes and survival. Case Presentation . We describe the case of DGAA in two siblings, in which the diagnostic time point, treatment, and outcomes were completely different. The girl was diagnosed with DGAA at the age of 6 months during investigations for poor weight gain and excessive sleepiness. The finding of severe cardiomyopathy through EKG and echocardiography led to the suspicion of storage disease, and the GAA deficiency was later confirmed by genetic analysis. The girl died of complications due to the clinical picture before starting ERT. Conversely, her younger brother had the opportunity to receive an early diagnosis and the rapid onset of ERT. He is showing a regression of cardiac hypertrophy. Conclusion . The advent of ERT improved clinical outcomes and survival in infantile‐onset PD. Its impact on cardiac function is still under study, but different reports in the literature have shown encouraging data. Early recognition of DGAA and prompt initiation of ERT is therefore crucial to prevent the progression of the disease and improve the outcomes.
- 1 January 2023
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2023 (1) , 8470341
Open AccessEnzyme Replacement Therapy (ERT) on Heart Function Changes the Outcome in Patients with Infantile‐Onset Pompe Disease: A Familial History
Background . Lysosomal acid alpha‐glucosidase (GAA) deficiency, also known as Pompe disease, is an autosomal recessive disorder that leads to the accumulation of glycogen in lysosomes and cytoplasm, resulting in tissue destruction. Infantile‐onset GAA deficiency is characterized by cardiomyopathy and severe generalized hypotonia. Without treatment, most patients die within the first two years of life. The demonstration of reduced GAA activity, followed by sequencing of the GAA gene, confirms the disease. GAA deficiency is currently treated with enzyme replacement therapy (ERT) with improved clinical outcomes and survival. Case Presentation . We describe the case of DGAA in two siblings, in which the diagnostic time point, treatment, and outcomes were completely different. The girl was diagnosed with DGAA at the age of 6 months during investigations for poor weight gain and excessive sleepiness. The finding of severe cardiomyopathy through EKG and echocardiography led to the suspicion of storage disease, and the GAA deficiency was later confirmed by genetic analysis. The girl died of complications due to the clinical picture before starting ERT. Conversely, her younger brother had the opportunity to receive an early diagnosis and the rapid onset of ERT. He is showing a regression of cardiac hypertrophy. Conclusion . The advent of ERT improved clinical outcomes and survival in infantile‐onset PD. Its impact on cardiac function is still under study, but different reports in the literature have shown encouraging data. Early recognition of DGAA and prompt initiation of ERT is therefore crucial to prevent the progression of the disease and improve the outcomes.
- Open Access
Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years
(1) Background: Changes in the clinical presentation of celiac disease (CD) in children have been reported. The guidelines of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) allow esophagogastroduodenoscopy (EGD) with biopsies to be avoided under specific circumstances. We aimed to assess the clinical picture of pediatric CD patients at diagnosis and to validate ESPGHAN non-biopsy criteria. (2) Methods: Patients with suspected CD or undergoing screening from 2004 to 2014 at the University Hospital in Modena, Italy were enrolled. The accuracy of ESPGHAN non-biopsy criteria and modified versions were assessed. (3) Results: In total, 410 patients were enrolled, of whom 403 were considered for analysis. Of the patients considered, 45 were asymptomatic and diagnosed with CD (11.2%) while 358 patients (88.2%) were symptomatic, of whom 295 were diagnosed with CD. Among symptomatic CD patients, 57 (19.3%) had gastrointestinal symptoms, 98 (33%) had atypical symptoms and 140 (47.4%) had both. No difference was found for the presence of gastrointestinal symptoms at different ages. The non-biopsy ESPGHAN criteria yielded an accuracy of 59.4% with a positive predictive value (PPV) of 100%; 173 out of 308 EGD (56.2%) could have been avoided. The modified 7× and 5× upper limit of normal cut-offs for IgA anti tissue-transglutaminase reached 60.7% and 64.3% of EGD avoided, respectively. (4) Conclusions: Over 10 years, late age at diagnosis and increased rates of atypical CD presentation were found. ESPGHAN non-biopsy criteria are accurate for CD diagnosis and allow half of unneeded EGD to be avoided. Modified versions allowed sparing a greater number of EGD.
Open AccessClinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years
(1) Background: Changes in the clinical presentation of celiac disease (CD) in children have been reported. The guidelines of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) allow esophagogastroduodenoscopy (EGD) with biopsies to be avoided under specific circumstances. We aimed to assess the clinical picture of pediatric CD patients at diagnosis and to validate ESPGHAN non-biopsy criteria. (2) Methods: Patients with suspected CD or undergoing screening from 2004 to 2014 at the University Hospital in Modena, Italy were enrolled. The accuracy of ESPGHAN non-biopsy criteria and modified versions were assessed. (3) Results: In total, 410 patients were enrolled, of whom 403 were considered for analysis. Of the patients considered, 45 were asymptomatic and diagnosed with CD (11.2%) while 358 patients (88.2%) were symptomatic, of whom 295 were diagnosed with CD. Among symptomatic CD patients, 57 (19.3%) had gastrointestinal symptoms, 98 (33%) had atypical symptoms and 140 (47.4%) had both. No difference was found for the presence of gastrointestinal symptoms at different ages. The non-biopsy ESPGHAN criteria yielded an accuracy of 59.4% with a positive predictive value (PPV) of 100%; 173 out of 308 EGD (56.2%) could have been avoided. The modified 7× and 5× upper limit of normal cut-offs for IgA anti tissue-transglutaminase reached 60.7% and 64.3% of EGD avoided, respectively. (4) Conclusions: Over 10 years, late age at diagnosis and increased rates of atypical CD presentation were found. ESPGHAN non-biopsy criteria are accurate for CD diagnosis and allow half of unneeded EGD to be avoided. Modified versions allowed sparing a greater number of EGD.
- Open Access
- 18 July 2021
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 47 (1) , 1-5
Brief comments on three existing approaches for managing neonates at risk of early-onset sepsis
Background: Growing concerns regarding the adverse effects of antibiotics during the first days of life and the marked reduction in the incidence of early-onset sepsis (EOS) are changing the clinical practice for managing neonates at risk of EOS. Strategies avoiding unnecessary antibiotics while promoting mother-infant bonding and breastfeeding deserve to be considered. Main body: We compare strategies for managing newborns at risk of EOS recommended by the American Academy of Pediatrics, which are among the most followed recommendations worldwide. Currently three different approaches are suggested in asymptomatic full-term or late preterm neonates: i) the conventional management, based on standard perinatal risk factors for EOS alone, ii) the neonatal sepsis calculator, a multivariate risk assessment based on individualized, quantitative risk estimates (relying on maternal risk factors for EOS) combined with physical examination findings at birth and in the following hours and iii) an approach entirely based on newborn clinical condition (serial clinical observation) during the first 48 h of life. We discuss advantages and limitations of these approaches, by analyzing studies supporting each strategy. Approximately 40% of infants who develop EOS cannot be identified on the basis of maternal RFs or laboratory tests, therefore close monitoring of the asymptomatic but at-risk infant remains crucial. A key question is to know what proportion of babies with mild, unspecific symptoms at birth can be managed safely without giving antibiotics. Conclusions: Both neonatal sepsis calculator and serial clinical observation may miss cases of EOS, and clinical vigilance for all neonates is essential There is a need to assess which symptoms at birth are more predictive of EOS, and therefore require immediate interventions, or symptoms that can be carefully reevaluated without necessarily treat immediately the neonate with antibiotics. Studies comparing strategies for managing neonates are recommended.
- 18 July 2021
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 47 (1) , 1-5
Open AccessBrief comments on three existing approaches for managing neonates at risk of early-onset sepsis
Background: Growing concerns regarding the adverse effects of antibiotics during the first days of life and the marked reduction in the incidence of early-onset sepsis (EOS) are changing the clinical practice for managing neonates at risk of EOS. Strategies avoiding unnecessary antibiotics while promoting mother-infant bonding and breastfeeding deserve to be considered. Main body: We compare strategies for managing newborns at risk of EOS recommended by the American Academy of Pediatrics, which are among the most followed recommendations worldwide. Currently three different approaches are suggested in asymptomatic full-term or late preterm neonates: i) the conventional management, based on standard perinatal risk factors for EOS alone, ii) the neonatal sepsis calculator, a multivariate risk assessment based on individualized, quantitative risk estimates (relying on maternal risk factors for EOS) combined with physical examination findings at birth and in the following hours and iii) an approach entirely based on newborn clinical condition (serial clinical observation) during the first 48 h of life. We discuss advantages and limitations of these approaches, by analyzing studies supporting each strategy. Approximately 40% of infants who develop EOS cannot be identified on the basis of maternal RFs or laboratory tests, therefore close monitoring of the asymptomatic but at-risk infant remains crucial. A key question is to know what proportion of babies with mild, unspecific symptoms at birth can be managed safely without giving antibiotics. Conclusions: Both neonatal sepsis calculator and serial clinical observation may miss cases of EOS, and clinical vigilance for all neonates is essential There is a need to assess which symptoms at birth are more predictive of EOS, and therefore require immediate interventions, or symptoms that can be carefully reevaluated without necessarily treat immediately the neonate with antibiotics. Studies comparing strategies for managing neonates are recommended.